STOCK TITAN

Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 8, 2024, to discuss the financial results for the fourth quarter and full year 2023, along with a business update and upcoming milestones.
Positive
  • None.
Negative
  • None.

BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may access the conference call by dialing, 1-844-481-2811 (U.S. and Canada Toll Free) or 1-412-317-0676 (International). Please direct the operator to be connected to the Sensus Healthcare conference call.

The call will be webcast live and can be accessed at this link, which also may be found in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

Following the conclusion of the conference call, a telephone replay will be available until March 8th, and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free), or 412-317-0088 (International).  At the system prompt, dial the replay code – 4664378 – followed by the # sign. Playback will automatically begin. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. 

For more information, visit www.sensushealthcare.com.

Contact:
LHA Investor Relations

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com


# # #


Sensus Healthcare will hold the conference call on February 8, 2024.

The ticker symbol for Sensus Healthcare is SRTS.

Participants can pre-register for the conference call using the provided link.

Participants without internet access can access the conference call by dialing the provided phone numbers.

The telephone replay of the conference call will be available until March 8th.
Sensus Healthcare Inc

NASDAQ:SRTS

SRTS Rankings

SRTS Latest News

SRTS Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Boca Raton

About SRTS

sensus healthcare, inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancer and keloids. sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (srt), which is a result of over a decade of dedicated research and development activities. sensus has successfully incorporated the srt therapy into its portfolio of treatment devices: srt-100™ and srt-100 vision™. srt technology effectively and safely treats oncological and non-oncological skin conditions. for more information, visit http://www.sensushealthcare.com.